Brief: Shanghai Junshi Biosciences Says NMPA Accepts New Drug Applications For Toripalimab-Injection
09/03/2026 17:13
March 9 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS: ACCEPTANCE OF NEW DRUG APPLICATIONS FOR TORIPALIMAB- INJECTION BY NMPA Further company coverage: 688180.SS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab